ReviewLast verified: 2026-05-07
BPC-157: What It Is, What the Research Actually Shows, and What's Coming Next
Read →Reclassification pending
Start Here
Compound Reviews
Physician-authored overviews of mechanism, evidence, and regulatory status. Written for patients and clinicians.
ReviewLast verified: 2026-05-07
TB-500 (Thymosin Beta-4): What It Is, What the Research Actually Shows, and What's Coming Next
Read →Reclassification pending
ReviewLast verified: 2026-05-07
CJC-1295 & Ipamorelin: What They Are, What the Research Actually Shows, and What's Coming Next
Read →Reclassification pending
ReviewLast verified: 2026-05-07
GHK-Cu: What It Is, What the Research Actually Shows, and What's Coming Next
Read →Reclassification pending
ReviewLast verified: 2026-05-07
Thymosin Alpha-1: What It Is, What the Research Actually Shows, and What's Coming Next
Read →Reclassification pending
ReviewLast verified: 2026-05-07
AOD-9604: What It Is, What the Research Actually Shows, and What's Coming Next
Read →Reclassification pending
Primary Research & Sources
Peer-reviewed studies from PubMed and clinical journals
10 items
RegulatoryLast verified: 2026-05-02
FDA Finalizes Reclassification of Seven Compounded Peptides, April 2026
FDA finalized the reclassification of seven peptides previously available through 503A compounding pharmacies. BPC-157, TB-500, KPV, DSIP, Epitalon, LL-37, Selank, Semax, and Melanotan II are no longer eligible for traditional compounding. Advisory panel for remaining peptides scheduled July 2026.
bpc-157tb-500kpvdsipepitalonll-37selanksemaxmelanotan-iifda-reclassificationcompoundingregulation
Read →Reclassification pending
Truthe take: This is the regulatory event we have been tracking since 2024. Some compounds in our protocols are affected. We have updated our formulary and our patients have been notified. The July panel will determine the next wave.
ResearchLast verified: 2026-05-02
Growth Hormone Releasing Hormone Analog Sermorelin: Clinical Applications and Pharmacology
Review of sermorelin as a GHRH analog for restoring pulsatile growth hormone secretion. Documented safety profile in adults with age-related GH decline. Does not suppress endogenous GH production, unlike exogenous GH.
sermorelinsermorelingrowth-hormone
Read →Legal to Compound
Truthe take: Sermorelin is the reason we use GHRH analogs instead of injecting growth hormone directly. It restores the body's own pulsatile pattern. Safer, more physiologic, less regulatory risk.
Truthe is a patient acquisition and marketing platform. All clinical decisions, prescriptions, and medical oversight are provided by independently licensed physicians and pharmacies. Content published here is for informational purposes and does not replace professional medical advice.